9. Introduction to signal detection

Slides:



Advertisements
Similar presentations
Introduction to Impact Assessment
Advertisements

Susan Burner Bankowski, M.S., J.D. Chair, OHSU IRB
Safety Reporting IN Clinical Trials
Copyright © Healthcare Quality Quest, Proposed standards for a national clinical audit — How we got involved and what we have learned.
Study Designs in Epidemiologic
Elements of a clinical trial research protocol
1 MANUFACTURING AND PRODUCTION OF BIOLOGICAL PRODUCTS (ERT 455) HAZARD ANALYSIS AND CRITICAL CONTROL POINT (HACCP) SYSTEM Munira Mohamed Nazari School.
Capturing and Reporting Adverse Events in Clinical Research
Creating Architectural Descriptions. Outline Standardizing architectural descriptions: The IEEE has published, “Recommended Practice for Architectural.
Surveillance. Definition Continuous and systematic process of collection, analysis, interpretation, and dissemination of descriptive information for monitoring.
Postmarketing Risk Assessment of Drug Products Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research.
Codex Guidelines for the Application of HACCP
 Pharmacovigilance – Patient’s standpoint Steve Arlington May 2007.
Adverse Events, Unanticipated Problems, Protocol Deviations & other Safety Information Which Form 4 to Use?
SERIOUS ADVERSE EVENTS REPORTING Elizabeth Dayag IRB Administrator Naval Medical Center Portsmouth.
Adverse Events and Unanticipated Problems Presented by: Karen Jeans, PhD, CCRN, CIP COACH Program Analyst.
Clinical causality assessment I. Ralph Edwards R.H.B Meyboom.
1 Nuts and Bolts of Safety Reporting The Role of the CRO Dr. Noa Lowenton Spier Pharma-Clinical S.A.G.
Medical Audit.
H. Lundbeck A/S21-Sep-151 Pharmacovigilance during clinical development SAE reporting, ASUR and PSUR IFF Seminar, 21. February 2007.
Prescribing Errors in General Practice The PRACtICe Study (2012) GMC Investigating Prevalence and Causes.
Collecting data in clinic.  Aim of BADBIR  Definition of Adverse Events  Adverse events in BADBIR  Adverse event recording in hospital case notes.
Preventing Surgical Complications Prevent Harm from High Alert Medication- Anticoagulants in Primary Care Insert Date here Presenter:
PHARMACOVIGILANCE AND CLINICAL TRIALS DIVISION 20 August 2015 Victoria Falls Protecting Your Right to Quality Medicines and Medical Devices.
Topic 6 Understanding and managing clinical risk.
Reproductive Health Drugs, Pregnancy Labeling Subcommittee Meeting March 28-29, 2000 Holli A. Hamilton, M.D., M.P.H. Pregnancy Labeling Team Office of.
Ergonomics Regulatory Requirements Bawan Saravanabawan, Labour Program, HRSDC February 4, 2008.
DEVELOPING EVIDENCE ON VACCINE SAFETY Susan S. Ellenberg, Ph.D. Center for Clinical Epidemiology and Biostatistics U Penn School of Medicine Global Vaccines.
EAE Training EAE Reporting and Assessment Overview DAIDS Regional Training Event, Regulatory Compliance Center Kampala, Uganda, September 2009 DAIDS Regional.
CAUSALITY ASSESSMENT OF SUSPECTED AEs Dr. Retesh Kumar Head, Global PhV Department 12/13/2015.
Signal identification and development I.Ralph Edwards.
Dr Mary Couper Quality Assurance and Safety of Medicines WHO
Minimum requirements for Pharmacovigilance in countries.
European Patients’ Academy on Therapeutic Innovation Introduction to pharmacovigilance Monitoring the safety of medicines.
EBM --- Journal Reading Presenter :黃美琴 Date : 2005/10/27.
Module 6 Monitoring Events Supposedly Attributable to Vaccination or Immunization (ESAVIs) Training for Inactivated Poliovirus Vaccine (IPV) introduction.
27 June 2000Victor F. C. Raczkowski, M.D.1 Risk-Management Options Victor F. C. Raczkowski, M.D., M.S. Gastrointestinal Drugs Advisory Committee 27 June.
Complaint Handling Medical Device Reporting May 19, 2016 Rita Harden, Director Customer Relations & Regulatory Reporting.
Social Pharmacy and Pharmacovigilance
Principles of Risk Management
Detection & monitoring of ADR
Monitoring and Evaluation: A Review of Terms
11 vi. Define schedules and routes for data collection and reporting
5. National and international reporting of adverse events: mechanisms, routes and resources Multi-partner training package on active TB drug safety monitoring.
Risk Communication in Medicines
11 vii. Consolidate aDSM data electronically
EudraVigilance.
8. Causality assessment:
11 viii. Develop capacity for signal detection and causality assessment Multi-partner training package on active TB drug safety monitoring and management.
11 ii. Develop a plan for aDSM
1. Structure and training objectives for this course & key references
Within Trial Decisions: Unblinding and Termination
12. Role of national and international technical and funding partners in the implementation of aDSM Multi-partner training package on active TB drug safety.
Remote Monitoring of Adverse Events
11 i. Create a national coordinating mechanism for aDSM
3. Key definitions Multi-partner training package on active TB drug safety monitoring and management (aDSM) July 2016.
FDA Guidance for Industry and FDA Staff Summary of Public Notification of Emerging Postmarket Medical Device Signals (“Emerging Signals”) Effective: December.
Pharmacovigilance in clinical trials
10. Overview on risk communication and new knowledge integration
ISPM 8: Pest Status of on Area
Quality Risk Management
Developing pharmacovigilance: new challenges and opportunities Mary Couper and Shanthi Pal Quality Assurance and Safety of Medicines.
CD-JEV AEFI monitoring
Helen Lee, European Commission
SERIOUS ADVERSE EVENTS REPORTING
7. aDSM slides - Indicators of aDSM implementation and programme management Multi-partner training package on active TB drug safety monitoring and management.
Regulatory Oversight of HOF in Finland
Christine Halleux, MD, PhD
Introduction to public health surveillance
11 iii. Define management and supervision roles and responsibilities
Presentation transcript:

9. Introduction to signal detection Multi-partner training package on active TB drug safety monitoring and management (aDSM) July 2016

Objective of the presentation By the end of this presentation, the participant is expected to be able to: describe the main aims and principles of signal detection and completion of safety profiles for new TB drugs and regimens

one of the main reasons we collect aDSM data Signal detection (1) one of the main reasons we collect aDSM data Programme indicators Causality assessment Signal detection Drug-safety profiles

Signal detection (2) definition of signal reported information on a possible causal relationship between an AE and a TB medicine the relationship was previously unknown or incompletely documented (e.g. a new aspect of a known association)

Signal detection (3) reporting (1) Signal detection is a continuous activity Analysis for completeness consistency timeliness number and type of events per facility and nationwide patterns over place and time Related to the number of patients exposed

Signal detection (4) reporting (2) Construction of risk profile Definite, probable and possible relationship Communication to NTP and all MDR-TB facilities Signal detection would best be done over a large set of observations

pointers for when to investigate Signal detection (5) pointers for when to investigate Data quality is reliable Several reports show a credible and strong relationship between event and drug The event is of sufficient importance or interest : to require regulatory action to require advice to prescribers for scientific /clinical purposes

Signal detection (6) features usually >1 event with a similar, strong relationship to a medicine (“certain” or “probable“). Events coded as “possible” can be used as supporting evidence a cluster of unexpected deaths coded as “possible” forms an exception to this general rule and will need to be taken seriously occasionally a single event (“certain” or “probable”) - notable for its severity, seriousness or distinctiveness - can be regarded as a signal

methods of signal identification Signal detection (7) methods of signal identification Clinical assessment of individual events Clinical review of collated events Record linkage Automated signal detection

Drug-safety profile (1) definition Drug-safety profile: a description of the benefits, risks and toxicity of a given TB drug or regimen, specifying any known or likely safety concerns, contraindications, cautions, preventive measures and other features that the user should be aware of to protect the health of a TB patient

Drug-safety profile (2) adding new knowledge on benefits & harms

Creating new knowledge

Conclusions Signal detection is an important process to improve knowledge on the new TB medicines and complete the safety profile of a new drug When monitoring AEs it is important to look beyond adverse reactions and biological pathways already linked to particular drugs: previously unknown or rare associations may occur, especially for newly released drugs Reports of adverse events to the global aDSM database is expected to improve the likelihood of picking up signals